Chembio’s DPP SARS-CoV-2 antigen test has received regulatory clearance from Brazil’s health regulator ANVISA.

The 20-minute test detects viral antigens specific to SARS-CoV-2 to determine if a patient is currently infected with the virus. The test kit includes a test cartridge, a minimally invasive nasal swab and a micro-reader.

The antigen test, which can be used in point-of-care settings, has 96 percent sensitivity and 98.7 percent specificity, the company said.